Breaking News, Financial News

Financial Report: Alkermes

Revenues up 13%, loss narrows

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes 2Q Revenues: $139.8 million (+13%) 2Q Loss: $7.8 million (loss of $16.7 million 2Q12) YTD Revenues: $278.4 million (+1%) YTD Loss: $428 million (earnings were $5.7 million YTD12) Comments: Revenues from the company’s five key commercial products grew 38% to $101.5 million in the quarter. Manufacturing and royalty revenues from its long-acting, atypical antipsychotic franchise, Risperdal Consta and Invega Sustenna/Xeplion, were $62.6 million, up 24%. Manufacturing and royalty revenu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters